Methylated SEPT9 assay-based liquid biopsy as a biomarker in molecular targeted agent-treated hepatocellular carcinoma.

Issei SaekiYutaka SuehiroYurika YamauchiTomomi HoshidaNorikazu TanabeTakashi OonoDaiki KawamotoTatsuro NishimuraToshihiko MatsumotoTsuyoshi IshikawaMototsugu ShimokawaAkihiro TamoriNorifumi KawadaYasuyuki TamaiMotoh IwasaHayato NakagawaHiroaki NaganoTaro TakamiTakahiro Yamasaki

Published in: Hepatology international (2023)

m-SEPT9 could be a potential predictive biomarker for survival in patients with HCC treated with MTAs.

Keyphrases

high throughput
newly diagnosed
risk assessment
single molecule
human health